Skip to main content
. 1998 Aug;72(8):6362–6372. doi: 10.1128/jvi.72.8.6362-6372.1998

TABLE 1.

Synthetic oligonucleotides used for retrotranscription and amplification of FMDV genomes

Fragmenta Oligonucleotide sequence (5′ to 3′) Orientation
F1 (1–367) TTGAAAGGGGGCGCTAGGGTC Sense
GTTAACTGAAAGGCGGGTTTCGGGTG Antisense
F2 (368–973) TAAGTTTTACCGTCTGTCCCG Sense
AAACCGAGCGCTTTTATAG Antisense
F3 (569–1643) CACGATCTAAGCAGGTTTCC Sense
CCCTTGAGCTTTCGCT Antisense
F4 (1002–4189) CGGAGGTCGGCACCTTTCCTTTAC Sense
CAAACGTGCTGTCCAGAATCTC Antisense
F5 (3988–5699) TTGGTGTCTGCTTTTGAGGAAC Sense
GCCTTCTGACCTGGAAGAGTTC Antisense
F6 (5344–7156) AAAGGCCAACACGAGGCAGC Sense
CGTCGACAATGCGAGTCTTGCCG Antisense
F7 (6610–8115) GGGTTGATCGTTGATACCAGAGA Sense
GGATTAAGGAAGCCGGGAAAGCCC Antisense
C1 (3573–4189) ACACCGTGTGTTGGCTACGGCG Sense
CAAACGTGCTGTCCAGAATCTC Antisense
C2 (2817–4189) CTTGGCCGGTTTGGCCCAGTAC Sense
CAAACGTGCTGTCCAGAATCTC Antisense
C3 (1009–3534) CGGCACCTTTCCTTTTATAACC Sense
CTTGTGGTAGGCAGTGGGATTGGTT GTGTTGTTAAGTG Antisense
a

Amplified fragments of FMDV serotype C and chimeric type O-type C genomes are designated by F and C, respectively; numbers in parentheses indicate the oligonucleotide positions in the C-S8c1 genome, numbered as described in Materials and Methods (20). 

HHS Vulnerability Disclosure